Company intelligence / Profile preview
Sotira
Phoenix, Arizona, United Statessotira-scientific.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sotira developed KEPTIDE™, an intranasal peptide designed to block the ACE2 receptor, preventing SARS-CoV‑2 entry into human cells. Preclinical studies showed protection against lung and kidney injury and prevention of acute death response in animal models. As of late 2020, the product was under FDA review with plans to enter Phase 1 human trials in spring 2021. No published results from human clinical trials are available.
- Therapeutic areas
- Infectious Diseases
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Coppe Laboratories
Beyond the preview
Go deeper on Sotira.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sotira.